These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28279153)

  • 21. Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.
    Pivonello R; Auriemma RS; Grasso LF; Pivonello C; Simeoli C; Patalano R; Galdiero M; Colao A
    Pituitary; 2017 Feb; 20(1):46-62. PubMed ID: 28224405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry.
    Maione L; Brue T; Beckers A; Delemer B; Petrossians P; Borson-Chazot F; Chabre O; François P; Bertherat J; Cortet-Rudelli C; Chanson P;
    Eur J Endocrinol; 2017 May; 176(5):645-655. PubMed ID: 28246150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.
    Swearingen B; Barker FG; Katznelson L; Biller BM; Grinspoon S; Klibanski A; Moayeri N; Black PM; Zervas NT
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3419-26. PubMed ID: 9768641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease.
    Mercado M; Espinosa de los Monteros AL; Sosa E; Cheng S; Mendoza V; Hernández I; Sandoval C; Guinto G; Molina M
    Horm Res; 2004; 62(6):293-9. PubMed ID: 15542931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amelioration of cardiovascular risk factors with partial biochemical control of acromegaly.
    Delaroudis SP; Efstathiadou ZA; Koukoulis GN; Kita MD; Farmakiotis D; Dara OG; Goulis DG; Makedou A; Makris P; Slavakis A; Avramides AI
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):279-84. PubMed ID: 18194486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
    Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
    J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High prevalence of colonic polyps in patients with acromegaly. Influence of sex and age.
    Terzolo M; Tappero G; Borretta G; Asnaghi G; Pia A; Reimondo G; Boccuzzi A; Cesario F; Rovero E; Paccotti P
    Arch Intern Med; 1994 Jun; 154(11):1272-6. PubMed ID: 8203994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.
    Berg C; Petersenn S; Lahner H; Herrmann BL; Buchfelder M; Droste M; Stalla GK; Strasburger CJ; Roggenbuck U; Lehmann N; Moebus S; Jöckel KH; Möhlenkamp S; Erbel R; Saller B; Mann K;
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3648-56. PubMed ID: 20463098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients.
    Evran M; Sert M; Tetiker T
    BMC Endocr Disord; 2014 Dec; 14():97. PubMed ID: 25511633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acromegaly in 2000].
    Gervaise N; Combe H; Lecomte P
    Ann Endocrinol (Paris); 2000 Sep; 61(3):242-52. PubMed ID: 10970950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of disease duration on coronary calcification in patients with acromegaly.
    Herrmann BL; Severing M; Schmermund A; Berg C; Budde T; Erbel R; Mann K
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):417-22. PubMed ID: 19373755
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study.
    Bogazzi F; Battolla L; Spinelli C; Rossi G; Gavioli S; Di Bello V; Cosci C; Sardella C; Volterrani D; Talini E; Pepe P; Falaschi F; Mariani G; Martino E
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4271-7. PubMed ID: 17785352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
    Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
    Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
    Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
    J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A; Terzolo M; Bondanelli M; Galderisi M; Vitale G; Reimondo G; Ambrosio MR; Pivonello R; Lombardi G; Angeli A; degli Uberti EC
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acromegaly: biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy.
    Serri O; Somma M; Comtois R; Rasio E; Beauregard H; Jilwan N; Hardy J
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1185-9. PubMed ID: 4055986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pure endoscopic transsphenoidal surgery for treatment of acromegaly: results of 67 cases treated in a pituitary center.
    Gondim JA; Almeida JP; de Albuquerque LA; Gomes E; Schops M; Ferraz T
    Neurosurg Focus; 2010 Oct; 29(4):E7. PubMed ID: 20887132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.